SE Asia Latest Target Market in Growing Global Distributor Network
HALIFAX, Aug. 5 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostics, announced today
that it has expanded its global distribution network into Southeast Asia,
where the Company's MiraWell(R) Rapid HIV Test (MiraWell HIV) will soon be
available to healthcare providers and their patients.
American Health Diagnostics LLC (AHD), a MedMira distribution agent in
the United States, has signed an exclusive distribution agreement for MiraWell
HIV in select markets of the Southeast Asia region. Under the terms of the
agreement AHD will purchase one million MiraWell HIV tests in the first year.
Technical training is slated to begin in August 2008 with product sales
ramping up throughout the year. AHD is working with its on-the-ground
sub-distributors, to market, sell and promote MiraWell HIV in the territory.
"Southeast Asia holds exciting market opportunities for MedMira and we
are very pleased to extend our reach into this target region through the AHD
channel," said Hermes Chan, President and CEO of MedMira. "Over the past five
years, we have worked closely with AHD to support Cardinal Health in
successfully marketing and selling our Reveal(R) G3 HIV test in the United
States. Based on this model, we look forward to working with AHD and their
sub-distribution partners to build a strong market base for MiraWell HIV and
additional MedMira products in the future."
MiraWell HIV is built on the Company's patented rapid flow-through
technology platform, which is the product engine behind MedMira's successful
line of rapid HIV tests that have been approved in Canada, the United States,
the European Union, China, Russia, and India. MiraWell HIV is approved by
China's State Food and Drug Administration (SFDA). The test requires no
specialized training or equipment to perform, and uses a whole blood, serum or
plasma specimen to deliver results in just three minutes. MiraWell HIV has an
extended shelf-life with no refrigeration required, making it ideally suited
for all types of testing environments. All of MedMira's tests are manufactured
in Canada under ISO and GMP standards.
"Our relationship with MedMira and experience with its products has been
excellent and we are confident that MiraWell HIV answers the need for quality
rapid diagnostics in the target market," said Brian Banks, President of AHD.
"We are excited to be working with our distribution partners who have the
strength and experience needed to successfully penetrate the target market and
establish a solid end-user customer base for the MiraWell HIV test."
According to the WHO's 2006 Global Report on AIDS (www.who.int), South
and Southeast Asia combined have approximately 7.6 million people living with
HIV/AIDS. The reported prevalence of the disease varies widely from country to
About American Health Diagnostics
American Health Diagnostics brings innovations to life through a
proprietary market readiness process and proven distribution management
network. The AHD market readiness and distribution management system has been
utilized to introduce MedMira's Reveal(R) Rapid HIV-1 Antibody Test the
market's fastest FDA approved HIV test and ThyroTec's ThyroTest(TM), the first
ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening
MedMira is a leading developer, manufacturer, and marketer of advanced
rapid diagnostics. Built on the Company's patented rapid flow-through
technology platform, MedMira's single and multiple rapid tests provide
hospitals, labs, clinics and individuals around the world with reliable,
diagnosis for diseases such as HIV and hepatitis C in just three minutes. The
company's tests, which are sold under the Reveal(R), MiraWell(R), MiraCare(TM)
and Multiplo(TM) brands in global markets, have achieved regulatory approvals
in Canada, the United States, China, Russia, India, and the European Union.
MedMira is an approved supplier to US Agency for International Development
(USAID) and the Pan American Health Organization (PAHO).
In 2006, MedMira launched the Maple Biosciences division to develop and
commercialize diagnostic instruments based on biosensor technology platforms.
For more information visit www.maplebio.com.
MedMira's corporate offices, R&D, and manufacturing facilities are
located in Halifax, Nova Scotia, Canada. For more information visit MedMira's
website at www.medmira.com.
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, firstname.lastname@example.org